BRIEF-LivaNova says breaching co to pay $6 mln if deal with Microport collapses Mon, 20 Nov 2017 11:40:04 +0000 Nov 20 (Reuters) - Microport Scientific Corp * LivaNova - If deal to sell co's cardiac rhythm management business to Microport Cardiac Rhythm terminated, breaching party to pay termination fee of $6 million ...
BRIEF-Microport Scientific's unit buys CRM business from Livanova Mon, 20 Nov 2017 10:07:13 +0000 Nov 20 (Reuters) - Microport Scientific Corp: * Announces acquisition of CRM business from Livanova PLC * Unit buys CRM business for initial consideration of US$190 million from Livanova PLC Source ...
4 Top Growth Picks to Avoid Tax Tangle in MedTech Tue, 14 Nov 2017 15:14:03 +0000 Despite the ongoing tax bill-related disputes in the MedTech industry, these stocks with high growth potential can be great bets for investors.
LivaNova posts 3Q profit Thu, 02 Nov 2017 12:25:56 +0000 The London-based company said it had profit of 57 cents per share. Earnings, adjusted for non-recurring costs, came to 93 cents per share. The medical technology company posted revenue of $309.7 million ...
ETFs with exposure to LivaNova Plc : October 20, 2017 Fri, 20 Oct 2017 14:17:51 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to LivaNova Plc Here are 5 ETFs with the largest exposure to LIVN-US. Comparing the performance and risk of LivaNova Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
LivaNova Receives FDA Approvals for SenTiva Device and Next-Generation VNS Therapy Programming System for Treatment of Epilepsy Mon, 09 Oct 2017 12:00:00 +0000 LivaNova PLC , a market-leading medical technology company, today announced it received U.S. Food and Drug Administration approvals for its latest Vagus Nerve Stimulation Therapy® System, which consists of the SenTiva™ implantable generator and the next-generation VNS Therapy Programming System for the treatment of patients with drug-resistant epilepsy.
LivaNova Plc :LIVN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Fri, 06 Oct 2017 13:07:56 +0000 Categories: Yahoo FinanceGet free summary analysis LivaNova Plc reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 321.39 million, Net Earnings of USD 47.50 million. Gross margins widened from 57.34% to 61.95% compared to the same period last year, operating (EBITDA) margins now 17.45% from 16.53%. Change in operating cash ... Read more
(Read more...)
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.